VMI
VHCP Management II Portfolio holdings
AUM
$379M
1-Year Est. Return
421.62%
This Fund
S&P 500
1 Year Est. Return
+421.62%
AUM
$379M
AUM Growth
+$117M
(+45%)
Holding
29
Top Buys
| 1 | +$22.3M | |
| 2 | +$3.59M | |
| 3 | +$3.49M | |
| 4 |
ADVM
Adverum Biotechnologies
ADVM
|
+$3.38M |
| 5 |
MRSN
Mersana Therapeutics
MRSN
|
+$2.7M |
Top Sells
| 1 | +$22.6M | |
| 2 | +$16M | |
| 3 | +$13.2M | |
| 4 |
BHVN
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
|
+$12.4M |
| 5 |
BioCryst Pharmaceuticals
BCRX
|
+$8.24M |
Sector Composition
| 1 | Healthcare | 99.09% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
RARX
26
DELISTED
Ra Pharmaceuticals, Inc. Common Stock
RARX
| – | – |
-677,164
|
|
||
|
27
BioCryst Pharmaceuticals
BCRX
$2.16B
| – | – |
-2,874,602
|
|
||
|
PRVL
28
DELISTED
Prevail Therapeutics Inc. Common Stock
PRVL
| – | – |
-2,604
|
|
||
|
LJPC
29
DELISTED
La Jolla Pharmaceutical Company
LJPC
| – | – |
-518,102
|
|